Question 1

What is Dolutegravir?

Accepted Answer

Dolutegravir is a Other.

Question 2

How often does Dolutegravir appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 56 articles.

Question 3

When was Dolutegravir first tracked by Ergen?

Accepted Answer

First tracked on Jun 09, 2026.

Question 4

When was Dolutegravir last mentioned in news?

Accepted Answer

Last active on Jun 10, 2026.

Question 5

What is Dolutegravir's current news sentiment?

Accepted Answer

Aggregate sentiment score: -20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Dolutegravir in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Dolutegravir?

Accepted Answer

GSK acquires Nuvalent for $10.6B (Jun 09, 2026, 56 articles).

Question 8

How did the "GSK acquires Nuvalent for $10.6B" event impact Dolutegravir?

Accepted Answer

The impending patent expiration of Dolutegravir>>>, an HIV drug, is a key driver for GSK plc>>>'s strategy to acquire new revenue streams through deals like the GSK plc>>> acquisition.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.